Satoh K, Miura I, Chubachi A, Utsumi S, Imai H, Miura A B
Department of Internal Medicine, Honma Hospital, Sakata.
Intern Med. 1996 Aug;35(8):660-2. doi: 10.2169/internalmedicine.35.660.
A 42-year-old woman with Crow-Fukase syndrome developed acute myeloid leukemia (M6: FAB classification) following treatment with alkylating agents (a total of 2,500 mg of melphalan and 9,800 mg of cyclophosphamide). Chromosome analysis of the bone marrow showed 49,XX,der(1;7)(q10;p10), +8, +19, +21 in therapy-related myelodysplastic syndrome with additional chromosomes 8, and 12 and two additional chromosomes 21 in acute leukemia. Because of the risk of therapy-related leukemia, alkylating agents should be used with caution in the treatment of Crow-Fukase syndrome.
一名患有克劳-深泽综合征的42岁女性在接受烷化剂治疗（总共使用了2500毫克美法仑和9800毫克环磷酰胺）后发生了急性髓系白血病（FAB分类：M6）。骨髓染色体分析显示，在治疗相关的骨髓增生异常综合征中存在49,XX,der(1;7)(q10;p10), +8, +19, +21，在急性白血病中额外有染色体8和12以及两条额外的染色体21。由于存在治疗相关白血病的风险，在克劳-深泽综合征的治疗中应谨慎使用烷化剂。
